医学
肝移植
队列
移植
入射(几何)
机器灌注
内科学
外科
并发症
胃肠病学
物理
光学
作者
Emil Bluhme,Markus Gäbel,L. Martínez de la Maza,Vera Nilsén,Karin Hildebrand,Jenni Jarsäter,Cecilia Bååth,Matilda Proos,Antonio Romano,Christina Villard,Gabriel C. Oniscu,Niklas Gustafsson,M.C. Thompson,Christoffer Hansson,Margareta Löfstedt,Jonas Andersson Lindholm,Lars Falk,William Bennet,Carl Jorns
标识
DOI:10.1097/lvt.0000000000000434
摘要
Liver transplantation using donors after controlled circulatory death (cDCD) is associated with poorer graft survival and increased incidence of non-anastomotic biliary strictures (NAS) compared to livers procured from brain dead donors (DBD). The use of Normothermic regional perfusion (NRP) during cDCD procurement may improve post-transplant outcome and reduce the incidence of NAS. In Sweden cDCD liver transplantation was introduced through a national pilot protocol with mandatory NRP. This study aims to evaluate the outcome of cDCD liver transplantation during the pilot period. Donor and recipient data were collected on all cDCD liver transplants during the pilot period between 2020 – December 2022. Outcome on NAS, patient- and graft survival, early allograft dysfunction, acute kidney injury, and comprehensive complication index was compared to a matched cohort of 28 patients transplanted with a DBD liver between 2018-2022. 18 patients were transplanted with a liver from a cDCD donor after using NRP. Mean functional warm ischemia time was 29±6 minutes. Mean lactate reduction during NRP was 8.7±2.4 mmol/L, end NRP perfusate ALT was 1.4±1 µkat/L. When comparing cDCD liver transplant recipients to DBD, no significant differences were observed in the incidence of NAS, patient and graft survival, comprehensive complication index, early allograft dysfunction, nor acute kidney injury. Study protocol MRCP in cDCD patients showed no signs of subclinical biliary strictures. Evaluation of the Swedish national pilot of cDCD liver transplantation with mandatory NRP shows comparable outcomes to a matched DBD cohort with 94.4 one-year patient and graft survival and no incidence of NAS within the first year.
科研通智能强力驱动
Strongly Powered by AbleSci AI